HIMS Hims & Hers Health, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Consumer-first digital health platform offering telehealth consultations, personalized prescription and non-prescription products, and laboratory testing
• • New 2025 offerings: Testosterone, menopause, perimenopause support, and comprehensive laboratory testing for early health risk identification
• • Strategic shift: Accelerated international expansion including pending acquisition of Australia-based Zava, enhancing global footprint across 5 countries
• • Quantitative note: Over 50 million telehealth consultations facilitated since founding, with extended operations in US, UK, Canada, EU (Germany, Ireland, France, Spain)
• • Noteworthy fact: Integrated ownership of 4 pharmacies and specialty facilities (compounding, peptide manufacturing, lab), reducing costs and improving operational control

Risk Factors

• • Cybersecurity risks reviewed quarterly by Audit Committee with escalation to CTO and executive leadership
• • Head of Information Security with 20 years experience, certified CISSP, CCSP, CRISC, CCISO, reporting to CTO
• • Dedicated cybersecurity team with industry-recognized credentials maintaining current professional education

Management Discussion & Analysis

• • Revenue $2.35B in 2025, up 59% YoY from $1.48B in 2024, driven by U.S. Revenue growth $2.21B (+53%) and Rest of World Revenue $134M (+399%)
• • Online Revenue $2.31B in 2025, up 61% YoY from $1.44B; Wholesale Revenue $36.2M down 6% YoY from $38.6M
• • Subscribers 2.51M in 2025, up 13% YoY from 2.23M; Monthly Revenue per Average Subscriber $83 (+28%) vs $65
• • Operating investments in facilities, marketing, product development; recent acquisitions including Zava (July 2025) and Medici (Nov 2025)
• • Forward outlook: 2026 acquisition of Eucalyptus ($1.15B total consideration) to expand international presence; expect continued growth but risks from marketing effectiveness, regulatory changes, and macroeconomic factors

What are the latest HIMS SEC filings in 2026?

Hims & Hers Health, Inc. (HIMS) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on July 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HIMS file its most recent 10-K annual report?

Hims & Hers Health, Inc. (HIMS) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HIMS 10-Q quarterly reports?

Hims & Hers Health, Inc. (HIMS)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every HIMS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HIMS filed recently?

Hims & Hers Health, Inc. (HIMS)'s most recent 8-K was filed on July 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HIMS insider trading activity (Form 4)?

SignalX aggregates every HIMS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HIMS file with the SEC?

Hims & Hers Health, Inc. (HIMS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HIMS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Hims & Hers Health, Inc. (HIMS).

What is HIMS's SEC CIK number?

Hims & Hers Health, Inc. (HIMS)'s SEC CIK (Central Index Key) number is 1773751. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1773751 to look up all HIMS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HIMS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Hims & Hers Health, Inc. (HIMS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.